AUTHORS
Christina Estes, MD, Susan Waples2, Emily DePew, CRNP3, Kathryn Mercer, CRNP4, Kylie Murphy, RN5, Jennifer Gary6, Alex Short7, Anisa Xhaja, MHA, MSHQS, LSSBB8, Baylie Mullinax, RN9, Diego A. De Idiaquez Bakula, MD10, Radhika Gangaraju, MD, MSPH11, Rushil Virendra Patel, MD12, Jori May, MD13
AFFILIATIONS
1 Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
2 Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
3 Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
4 Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
5 Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
6 Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
7 UAB Medicine, Birmingham, Alabama, United States
8 UAB Medicine, Birmingham, Alabama, United States
9 Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
10 Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
11 Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
12 Division of Gerontology, Geriatrics, and Palliative Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States, Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
13 Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
ABSTRACT
Introduction: Due to physician shortages and rising referral volumes, access to timely evaluation in classical hematology clinics is increasingly challenging. To expedite patient care and optimize clinician time, we created the Cell Count Triage (CCT) Clinic, designed to utilize Advanced Practice Providers (APPs) to rapidly evaluate patients referred for cytopenias and cytoses.
Methods: CCT Clinic was implemented by a classical hematology practice at a tertiary referral center. The practice includes 2 APPs (total 14 half-day clinic sessions per week) and 4 hematologists (total 6 half-day clinic sessions per week). CCT Clinic was incorporated into the existing schedules of the 2 APPs, with both APPs offering one 1-hour CCT appointment per half-day clinic session. Prior to scheduling, all records were reviewed, initially by a physician but subsequently by a trained nurse, and patients with non-severe cytopenias and cytosis were scheduled for CCT appointments (platelets 75×10⁹/L to 1,000×10⁹/L, hemoglobin 9g/dL to 19g/dL, leukopenia with absolute neutrophil count >1000 cells/μL, and leukocytosis with white blood cell count <20 cells/μL). Physicians and APPs collaborated to create a written diagnostic algorithm for 6 referral diagnoses: cytopenias (anemia, leukopenia, thrombocytopenia) and cytoses (erythrocytosis, leukocytosis, thrombocytosis). Each algorithm included components of the history, physical exam, and laboratory testing recommended for the respective cell line abnormality. APPs used the written algorithms to guide their evaluation, and physicians were readily available to discuss any remaining clinical questions.
After 6 months (September 2025 to February 2026), we conducted a retrospective review of patients evaluated through the CCT Clinic. Data collected included referral date, date of initial APP evaluation, referral indication, clinic disposition, and final diagnosis. After the CCT appointment, patients were categorized as (1) discharged from hematology care, (2) scheduled for APP follow-up, or (3) escalated for physician evaluation. The primary outcome was time from referral to initial CCT appointment compared to time to physician appointments in the same 6-month interval. Secondary outcomes included patient disposition and diagnostic outcomes, with targeted analysis of common classical hematologic referral indications including cytopenias, erythrocytosis, and iron deficiency. The project was designated a quality improvement initiative and deemed exempt from IRB review
Results: A total of 141 patients were evaluated through the CCT Clinic during the 6-month study period. Referral indications included anemia (n=60, 42.6%), neutropenia/leukopenia (n=27, 19.1%), erythrocytosis (n=25, 17.7%), thrombocytopenia (n=16, 11.3%), thrombocytosis (n=14, 9.9%), pancytopenia (n=6, 4.3%), leukocytosis (n=4, 2.8%), and other (n=8, 5.7%). The median time from referral to APP appointment was 37 days (IQR, 21-62 days), compared to the approximate wait time for a physician appointment of 9 months. Following initial CCT appointment, 57% patients (n=81) required APP follow-up, 33.1% patients (n=47) were discharged from hematology care, and 9.2% of patients (n=13) required escalation to a physician appointment.
Final diagnoses were predominantly benign hematologic conditions. Among all neutropenia/leukopenia referrals, 48.1% (n=13) were confirmed to have Duffy-null associated neutrophil count. Among 25 patients referred for erythrocytosis, 88% (n=22) were diagnosed with secondary erythrocytosis. No patients were diagnosed with myeloproliferative neoplasms. Among 60 patients referred for anemia, 71.7%% (n=43) were diagnosed with iron deficiency. Malignancy was identified in 3 patients (2.1%): 1 patient with a plasma cell disorder, 1 with myelodysplastic syndrome, and 1 with rectal adenocarcinoma.
Conclusion: Implementation of an APP-led, algorithm-based CCT Clinic significantly improved timely access to hematology evaluation, while facilitating accurate identification and management of common classical hematologic conditions. Most referrals for abnormal blood counts represented benign conditions including Duffy-null associated neutrophil count, secondary erythrocytosis, and iron deficiency anemia. More than 90% of patients were managed without a physician visit, suggesting that APP-led triage clinics may represent an effective strategy to optimize hematology resources and improve access to specialized care.
DISCLOSURES
Christina Estes, MD: No relevant conflicts of interest to declare.